Cardiology / Cardiovascular
Cardiovascular guidance, trial updates, drug mechanisms and CPD resources for clinicians following rapidly changing prevention, heart failure and cardiometabolic evidence.
Latest Guidelines
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated in primary or secondary…
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers, or disopyramide), or who…
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or ocular hypertension—continue using established…
Sotatercept for treating pulmonary arterial hypertension
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and existing PAH therapy status…
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving clinical workflow efficiency in…
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part of a comprehensive cardiovascular…
Trial Radar
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared…
PHASE3Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20…
TrialEstablishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland
Acute stress-induced (Takotsubo cardiomyopathy) presents like a heart attack and is triggered by intense emotional or physical stress.…
TrialBarts Sex-CAD Database – Sex Hormones and Inflammatory Status in Coronary Artery Disease
There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring…
Clinical News
Man completes half marathon after two heart attacks
Key Takeaways for Clinical Practice Cardiac rehabilitation and secondary prevention can enable significant functional recovery post-myocardial infarction, with…
29 Jul 2026‘It was heartbreaking to attend a fertility appointment in a maternity unit’
Key Takeaways for Clinical Practice Fertility services co-location with maternity units causes significant emotional harm – patients experiencing…
28 Jul 2026Meet the teenagers calling for action on violence against women and girls
Teenage activists are mobilising public engagement on violence against women and girls (VAWG), highlighting widespread concern among younger…
16 Jul 2026The ‘heartbreaking’ OCD that can make you doubt your relationship
Relationship OCD is an underrecognised condition characterised by intrusive doubts about romantic partnerships, requiring greater clinical awareness for…
Relevant Mechanisms
Coagulation Factor Xa/IIa — DOACs
Coagulation Factor Xa/IIa — DOACs is a clinically relevant Drug Science explainer. The coagulation cascade proceeds via two convergent pathways…
MechanismGLP-1 Receptor Agonism
GLP-1 Receptor Agonism is a clinically relevant Drug Science explainer. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal…
MechanismHMG-CoA Reductase — Statins
HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step…
MechanismPCSK9 Inhibition
PCSK9 Inhibition is a clinically relevant Drug Science explainer. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted…
MechanismRAAS Pathway
RAAS Pathway is a clinically relevant Drug Science explainer. The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade governing blood pressure,…
CPD, Podcasts & Webinars
Follow Cardiology / Cardiovascular safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Cardiology / Cardiovascular
Choose guideline, trial, Drug Science and education updates for this specialty.